Arrowhead Pharmaceuticals– tag –
-
Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study
Novartis Switzerland Overview Novartis announced that its antibody-oligonucleotide conjugate (AOC) delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve a statistically significant improvement in the pr... -
Arrowhead’s siRNA Therapeutic Plozasiran Achieves Approximately 80% Triglyceride Reduction in Severe Hypertriglyceridemia Patients
TCTMD USA Overview Arrowhead Pharmaceuticals' siRNA therapeutic, plozasiran (Redemplo), demonstrated potent efficacy in SHASTA-3 and SHASTA-4 trials, reducing triglyceride levels by approximately 80% in patients with severe hypertriglyce... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
Arrowhead’s Plozasiran Achieves Up to 81% Triglyceride Reduction in Severe Hypertriglyceridemia Phase 3, Pressuring Ionis
Fierce Biotech USA Overview Arrowhead Pharmaceuticals has reported robust Phase 3 SHASTA-3 and SHASTA-4 trial data for its siRNA therapeutic, plozasiran, in patients with severe hypertriglyceridemia (sHTG), putting pressure on competitor... -
RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver
European Biotechnology Magazine Germany Overview RNA therapeutics are entering a 'second act' after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahe... -
Novartis’ Acquired RNA Therapeutic del-brax Achieves Phase 1/2 Success for Muscle-Wasting Diseases
BioPharma Dive USA Overview Novartis' RNA therapeutic del-brax, acquired through its $12 billion purchase of Avidity Pharmaceuticals, successfully completed a Phase 1/2 clinical trial for muscle-wasting diseases, achieving its primary en... -
Closing the Innovation Gap: Early CMC Risk Management and Robust Conjugation Strategies for ADCs and AOCs
Industry Publication Unknown Overview As Antibody-Drug Conjugates (ADCs) and Oligonucleotide-Drug Conjugates (AOCs) rapidly expand beyond oncology, early identification of Chemistry, Manufacturing, and Controls (CMC) risks and establishi... -
Avidity Biosciences Leads Muscle Disease Therapy with Antibody-Oligonucleotide Conjugates (AOCs): DM1 HARBINGER™ Trial Advances to Phase 3
Bitget Global Overview Avidity Biosciences is a leading company in Antibody-Oligonucleotide Conjugates (AOCs), developing novel RNA therapeutics for muscle diseases. Its lead candidate, delpacibart etedesiran (AOC 1001), is progressing i...
1